AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer - Gianni, L.; Romieu, G.; Lichinister, M.; Serrano, S.; Mansutti, M.; Pivot, X.; Mariani, P.; Andre, F.; Chan, Arlene; Lipatov, O.; Chan, S.; Wardley, A.; et al. (American Society of Clinical Oncology, 2013)